Metastatic urothelial carcinoma

From Wikipedia, the free encyclopedia
Jump to: navigation, search

The following considers the results of Chemotherapy on Metastatic urothelial carcinoma.

"Patients with refractory advanced or metastatic urothelial carcinoma derive only minor benefit from chemotherapy".[1]

Various studies have shown combination chemotherapy to have an effect. Treatment with chemotherapy and "infusion cisplatin and high-dose 5-fluorouracil/leucovorin (P-HDFL)" results in a median survival of 38 months.[2]

Donald Kaufman worked on a study using a combination of gemcitabine and cisplatin, which resulted in a median survival of 14.3 months.[3]

Generally speaking, treatment with chemotherapy will not with any amount of certainty, extend one's life.

References[edit]

  1. ^ Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ (2003). "Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study". Urol. Oncol. 21 (1): 21–6. doi:10.1016/S1078-1439(02)00207-7. PMID 12684123. 
  2. ^ Lin CC, Hsu CH, Huang CY, et al. (March 2007). "Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens". Urology 69 (3): 479–84. doi:10.1016/j.urology.2006.12.010. PMID 17382149. 
  3. ^ Kaufman D, Raghavan D, Carducci M, et al. (May 2000). "Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer". J. Clin. Oncol. 18 (9): 1921–7. PMID 10784633.